Can a targeted pill outsmart a tough lung cancer mutation?
NCT ID NCT05276726
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This trial is testing an oral drug called JAB-21822 in people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation along with an STK11 mutation. The study aims to see if the drug is safe, tolerable, and effective in shrinking tumors. Participants must have these specific genetic changes and either be untreated or have had prior standard therapy. The trial is in early phases, so it focuses on safety and preliminary signs of benefit.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JAB-21822, an oral drug that targets a specific genetic mutation (KRAS G12C) in cancer cells
- What this could lead to
- If successful, this could provide a new treatment option for people with a hard-to-treat form of lung cancer that has specific genetic changes.
- What could go wrong
- This is an early-phase trial, so the drug may not work as hoped or may cause side effects. The results are preliminary and need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research site01
RECRUITINGBeijing, Beijing Municipality, 100101, China
-
Research site010
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, 400000, China
-
Research site011
NOT_YET_RECRUITINGShenzhen, Guangdong, 518000, China
-
Research site012
NOT_YET_RECRUITINGChangsha, Hunan, 410000, China
-
Research site013
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 101100, China
-
Research site014
NOT_YET_RECRUITINGHohhot, Neimenggu, 010000, China
-
Research site015
NOT_YET_RECRUITINGChangchun, Jilin, 130000, China
-
Research site016
NOT_YET_RECRUITINGNanning, Guangxi, 530000, China
-
Research site017
NOT_YET_RECRUITINGShijiazhuang, Hebei, 050000, China
-
Research site018
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150000, China
-
Research site019
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310000, China
-
Research site02
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100089, China
-
Research site020
NOT_YET_RECRUITINGXi’an, Shanxi, 710000, China
-
Research site021
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100032, China
-
Research site03
NOT_YET_RECRUITINGHubei, Wuhan, 430060, China
-
Research site04
NOT_YET_RECRUITINGZhengzhou, Henan, 450000, China
-
Research site05
NOT_YET_RECRUITINGXiamen, Fujian, 361000, China
-
Research site06
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
-
Research site07
NOT_YET_RECRUITINGShenyang, Liaoning, 110000, China
-
Research site08
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100010, China
-
Research site09
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 100010, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?
- Herbal extract may ease the toll of lung cancer immunotherapy